OBJECTIVES: We implemented active surveillance for Guillain-Barré syndrome (GBS) following seasonal or H1N1 influenza vaccination among the Medicare population during the 2009-2010 influenza season. METHODS: We used weekly Medicare claims data to monitor vaccinations and subsequent hospitalizations with principal diagnosis code for GBS within 42 days. Group sequential testing assessed whether the observed GBS rate exceeded a critical limit based on the expected rate from 5 previous years adjusted for claims delay. We evaluated the lag between date of service and date of claims availability and used it for adjustment. RESULTS: By July 30, 2010 (after 26 interim surveillance tests), 14.0 million seasonal and 3.3 million H1N1 vaccinations had accrued. Taking into account claims delay appropriately lowered the critical limit during early monitoring. The observed GBS rate was below the critical limit throughout the surveillance. CONCLUSIONS: Medicare data contributed rapid safety monitoring among millions of 2009-2010 influenza vaccine recipients. Adjustment for claims delay facilitates early detection of potential safety issues. Although limited by lack of medical record review to confirm cases, this claims-based surveillance did not indicate a statistically significant elevated GBS rate following seasonal or H1N1 influenza vaccination.
OBJECTIVES: We implemented active surveillance for Guillain-Barré syndrome (GBS) following seasonal or H1N1 influenza vaccination among the Medicare population during the 2009-2010 influenza season. METHODS: We used weekly Medicare claims data to monitor vaccinations and subsequent hospitalizations with principal diagnosis code for GBS within 42 days. Group sequential testing assessed whether the observed GBS rate exceeded a critical limit based on the expected rate from 5 previous years adjusted for claims delay. We evaluated the lag between date of service and date of claims availability and used it for adjustment. RESULTS: By July 30, 2010 (after 26 interim surveillance tests), 14.0 million seasonal and 3.3 million H1N1 vaccinations had accrued. Taking into account claims delay appropriately lowered the critical limit during early monitoring. The observed GBS rate was below the critical limit throughout the surveillance. CONCLUSIONS: Medicare data contributed rapid safety monitoring among millions of 2009-2010 influenza vaccine recipients. Adjustment for claims delay facilitates early detection of potential safety issues. Although limited by lack of medical record review to confirm cases, this claims-based surveillance did not indicate a statistically significant elevated GBS rate following seasonal or H1N1 influenza vaccination.
Authors: Robert L Davis; Margarette Kolczak; Edwin Lewis; James Nordin; Michael Goodman; David K Shay; Richard Platt; Steven Black; Henry Shinefield; Robert T Chen Journal: Epidemiology Date: 2005-05 Impact factor: 4.822
Authors: Tracy A Lieu; Martin Kulldorff; Robert L Davis; Edwin M Lewis; Eric Weintraub; Katherine Yih; Ruihua Yin; Jeffrey S Brown; Richard Platt Journal: Med Care Date: 2007-10 Impact factor: 2.983
Authors: T J Safranek; D N Lawrence; L T Kurland; D H Culver; W C Wiederholt; N S Hayner; M T Osterholm; P O'Brien; J M Hughes Journal: Am J Epidemiol Date: 1991-05-01 Impact factor: 4.897
Authors: Dale R Burwen; Robert Ball; Wilson W Bryan; Hector S Izurieta; Lawrence La Voie; Neville A Gibbs; Rebecca Kliman; M Miles Braun Journal: Am J Prev Med Date: 2010-10 Impact factor: 5.043
Authors: Dale R Burwen; Lawrence La Voie; M Miles Braun; Peter Houck; Robert Ball Journal: Pharmacoepidemiol Drug Saf Date: 2007-07 Impact factor: 2.890
Authors: T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen Journal: N Engl J Med Date: 1998-12-17 Impact factor: 91.245
Authors: Irving Nachamkin; Sean V Shadomy; Anthony P Moran; Nancy Cox; Collette Fitzgerald; Huong Ung; Adrian T Corcoran; John K Iskander; Lawrence B Schonberger; Robert T Chen Journal: J Infect Dis Date: 2008-07-15 Impact factor: 5.226
Authors: L B Schonberger; D J Bregman; J Z Sullivan-Bolyai; R A Keenlyside; D W Ziegler; H F Retailliau; D L Eddins; J A Bryan Journal: Am J Epidemiol Date: 1979-08 Impact factor: 4.897
Authors: Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae Journal: Hum Vaccin Immunother Date: 2013-09-06 Impact factor: 3.452
Authors: Hector S Izurieta; Nicole Thadani; David K Shay; Yun Lu; Aaron Maurer; Ivo M Foppa; Riley Franks; Douglas Pratt; Richard A Forshee; Thomas MaCurdy; Chris Worrall; Andrew E Howery; Jeffrey Kelman Journal: Lancet Infect Dis Date: 2015-02-09 Impact factor: 25.071
Authors: Enrique Alcalde-Cabero; Javier Almazán-Isla; Fernando J García López; José Ramón Ara-Callizo; Fuencisla Avellanal; Carlos Casasnovas; Carlos Cemillán; José Ignacio Cuadrado; Jacinto Duarte; María Dolores Fernández-Pérez; Óscar Fernández; Juan Antonio García Merino; Rosa García Montero; Dolores Montero; Julio Pardo; Francisco Javier Rodríguez-Rivera; María Ruiz-Tovar; Jesús de Pedro-Cuesta Journal: BMC Neurol Date: 2016-05-21 Impact factor: 2.474
Authors: Weiling Katherine Yih; Martin Kulldorff; Sukhminder K Sandhu; Lauren Zichittella; Judith C Maro; David V Cole; Robert Jin; Alison Tse Kawai; Meghan A Baker; Chunfu Liu; Cheryl N McMahill-Walraven; Mano S Selvan; Richard Platt; Michael D Nguyen; Grace M Lee Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-17 Impact factor: 2.890